[company_age]4.0[/company_age][employees]2-10 employees[/employees][funding]Series A[/funding][description]Macomics is a biotechnology company pioneering the development of macrophage-modulating precision medicines for cancer treatment. With a deep understanding of macrophage biology and immunology, Macomics leverages its proprietary ENIGMAC™ discovery platform to identify and validate novel therapeutic targets. This platform integrates cutting-edge technologies like genomics, proteomics, and bioinformatics to accelerate the development of innovative therapies. Macomics' team comprises experienced scientists and drug developers with a proven track record in the pharmaceutical industry, demonstrating their commitment to advancing macrophage-targeted therapies and bringing new treatment options to cancer patients.[/description][ps]Precision medicines targeting tumor-associated macrophages for cancer treatment[/ps]